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A B S T R A C T
During sepsis, the alarmin HMGB1 is released from tissues and promotes systemic inﬂammation that results in
multi-organ damage, with the kidney particularly susceptible to injury. The severity of inﬂammation and pro-
damage signaling mediated by HMGB1 appears to be dependent on the alarmin's redox state. Therefore, we
examined HMGB1 redox in kidney cells during sepsis. Using intravital microscopy, CellROX labeling of kidneys
in live mice indicated increased ROS generation in the kidney perivascular endothelium and tubules during
lipopolysaccharide (LPS)-induced sepsis. Subsequent CellROX and MitoSOX labeling of LPS-stressed endothelial
and kidney proximal tubule cells demonstrated increased ROS generation in these cells as sepsis worsens.
Consequently, HMGB1 oxidation increased in the cytoplasm of kidney cells during its translocation from the
nucleus to the circulation, with the degree of oxidation dependent on the severity of sepsis, as measured in in
vivo mouse samples using a thiol assay and mass spectrometry (LC-MS/MS). The greater the oxidation of
HMGB1, the greater the ability of the alarmin to stimulate pro-inﬂammatory cyto-/chemokine release (measured
by Luminex Multiplex) and alter mitochondrial ATP generation (Luminescent ATP Detection Assay).
Administration of glutathione and thioredoxin inhibitors to cell cultures enhanced HMGB1 oxidation during
sepsis in endothelial and proximal tubule cells, respectively. In conclusion, as sepsis worsens, ROS generation
and HMGB1 oxidation increases in kidney cells, which enhances HMGB1's pro-inﬂammatory signaling.
Conversely, the glutathione and thioredoxin systems work to maintain the protein in its reduced state.
1. Introduction
Sepsis is a major cause of death in hospitalized patients [1]. During
sepsis, enhanced oxidative stress and stimulation of pro-inﬂammatory
cyto-/chemokines promote tissue damage, which leads to kidney and
other organ failure [2–4]. During the early onset of endotoxemia, pa-
thogen microbial elements referred to as pathogen-associated molecule
patterns (PAMPs) (including lipopolysaccharide - LPS) activate im-
mune, endothelial and epithelial cells by stimulating toll-like receptors
(TLRs) [5–7]. Activation of TLRs induces the rapid release of early pro-
damage signals, including damage-associated molecular patterns
(DAMPs) that are referred to as alarmins, into the circulation [8,9].
Once released into the circulation, these alarmin molecules stimulate
the release of pro-inﬂammatory factors and widen damage systemically.
A major alarmin that is released from tissues within the ﬁrst 24 h of
endotoxemia is High Mobility Group Box 1 protein (HMGB1). HMGB1
is typically found in the nucleus of a variety cells (including immune,
endothelial and epithelial cells) where it is bound to DNA. After acti-
vation of TLR on these cells [8], acetylation of HMGB1 triggers its
translocation from the nucleus to the circulation [10]. Once in the
circulation, HMGB1 interacts with a variety of target cell receptors
including RAGE, TLR2, and TLR4 [11–17] and stimulates release of pro-
inﬂammatory cyto-/chemokines [14,15,17–20]. As sepsis worsens, the
pro-damage eﬀects of HMGB1 worsens causing progressive tissue and
organ damage [21].
During sepsis, excessive ROS is generated by various cells and
multiple sources, including enhanced activity of NAPDH oxidase and
dehydrogenase/xanthine oxidase enzymes [22–29], altered mitochon-
drial bioenergetics [30], fatty acid oxidation (peroxisomal metabolism)
and impaired peroxisomal catalase activity [31]. Enhanced levels of
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ROS (superoxide, hydrogen peroxide, hydroxyl, etc.) promote the lapse
into septic shock by promoting a multitude of redox reactions
throughout tissues that subsequently alters protein and enzymatic
function, modulates changes in microcirculatory hemodynamics, and
stimulates vascular structural changes. HMGB1 is a target of such redox
reaction molecules [32,33]. HMGB1 contains two redox sensitive cy-
steine moieties (at positions C23 and C45) in its 215 amino acid
structure whose redox states greatly impact HMGB1 function [34].
When these cysteine residues are in reduced thiol form, the protein's
pro-damage signaling is minimal [35,36]. However, as oxidative stress
worsens and these thiols are oxidized to form a disulﬁde bond,
HMGB1's function shifts to promote severe inﬂammation.
In the present study, we examined the redox state of HMGB1 during
sepsis, the cellular compartment where HMGB1 redox is eﬀected, the
cellular antioxidants that keep HMGB1 reduced, and the eﬀect that
HMGB1 redox has on the proteins ability to stimulate cyto-/chemokine
release. Since the kidneys are particularly vulnerable to sepsis, we ex-
amined these phenomena in kidneys cells.
2. Materials and methods
2.1. Animals
The animal study protocol was in accordance with the NIH's Guide
for the Care and Use of Laboratory Animals, the American Veterinary
Medical Association (AVMA) guidelines and approved by the
Institutional Animal Care and Use Committee. C57BL male mice
aged>16 weeks were used in all experiments. Details of animal usage
are described in the Supplementary methods online.
2.2. Cell cultures
The endothelial cell line Ea.hy926, which are human umbilical vein
endothelial cells (HUVEC), and human kidney proximal tubule (HK-2)
cells (ATCC, Chicago, IL) were used in experiments. Details of cell
cultures are described in the Supplementary methods online.
2.3. Experimental protocol and analysis
Details of experimental protocols and analysis (including LPS
treatment, ROS measurement in the circulation, nuclear/cytoplasmic
fractionation, HMGB1 isolation, thiol measurement, LC-MS/MS ana-
lysis, glutathione/thioredoxin analysis, cyto-/chemokine analysis, ATP
measurement and statistical analysis) are described in the
Supplementary methods online.
3. Results and discussion
3.1. ROS generation
We ﬁrst examined total ROS levels in the circulation of animals 24 h
after LPS-induced sepsis. In these experiments, two diﬀerent doses of
LPS were administered intraperitoneally to separate sets of animals, a
low LPS dose (10 µg/kg) and a high LPS (1 mg/kg) dose. The low dose
increased ROS in the circulation only slightly in animals, although the
increase was not statistically signiﬁcantly (Fig. 1a). In contrast, the high
LPS dose resulted in a signiﬁcant increase in circulating ROS within
24 h after LPS delivery.
Since the kidney is especially susceptible to oxidative damage, we
examined ROS generation in kidneys during sepsis. To localize kidney
ROS generation, we intrarenally perfused the membrane permeable
ROS labeling dye CellROX into septic mice 24 h after LPS (1 mg/kg)
delivery and imaged exposed kidneys in live animals using real-time
intravital microscopy. CellROX reacts with oxidative molecules, such as
superoxide and hydroxyl, which are generated from NADPH oxidase,
xanthine oxidase and mitochondrial respiration. CellROX staining de-
monstrated enhanced ROS generation in the kidney perivascular en-
dothelium and tubules (Fig. 1b) during sepsis.
Due to the potential of kidney endothelial and tubule cells to pro-
duce ROS, we further examined ROS generation in endothelial
(HUVEC) and HK-2 cells during sepsis. We initially examined the time
course of ROS generation in these cells. In experiments, cultured cells
were separately treated with three diﬀerent doses of LPS; a low (1 µg/
ml), medium (10 µg/ml) or high (20 µg/ml) LPS dose to mimic mild-to-
severe sepsis, respectively. All doses increased ROS in both endothelial
and proximal tubule cells, although the highest dose promoted a dras-
tically greater generation of ROS (Fig. 1c,e; Supplemental Fig. 1). In
these experiments, cellular ROS was again detected in live cells by
CellROX. Since mitochondria are major producers of ROS, particularly
superoxide, we also measured mitochondrial speciﬁc ROS generation
using the dye MitoSOX. Similar to CellROX, MitoSOX is also membrane
permeable, with both dyes ﬂuorescing once they are oxidized and
bound to cellular DNA. Comparable to experiments with CellROX, mi-
tochondrial ROS generation was also signiﬁcantly elevated within 24 h
of treatment with LPS in endothelial and proximal tubule cells, with the
higher LPS doses prompting greater mitochondrial ROS generation in
both cell types (Fig. 1d,f; Supplemental Fig. 1).
3.2. HMGB1 redox
We have previously shown that during LPS-induced stress, HMGB1
undergoes nuclear-to-cytoplasmic translocation in kidney cells and is
then released into the circulation [37]. Therefore, we next examined
the redox state, and more speciﬁcally the thiol content of HMGB1,
during the protein's LPS-induced translocation and release. In these
experiments, HMGB1 thiol content was measured in HMGB1 isolated
from nuclear and cytoplasmic kidney fractionates and from the plasma
after LPS administration. These experiments used whole kidney frac-
tionates and did not distinguish between speciﬁc cell type diﬀerences in
HMGB1 redox (i.e. endothelial versus epithelial cells). When animals
were treated with a low dose of LPS (10 µg/kg) to mimic mild sepsis,
HMGB1 demonstrated increased oxidation in the cytoplasm and
Fig. 1. Oxidative stress is increased in the circulation and in the kidneys during sepsis. (A) Levels of ROS in the circulation of mice 24 h after administration of low (10 µg/kg) or
high (1 mg/kg) LPS dose. (B) ROS generation (as indicated by the green ﬂuorescence of CellROX staining) in exposed kidneys of live animals 24 h after LPS (1 mg/kg) delivery. CellROX
staining of kidneys was visualized by real-time intravital microscopy. The perivasculature is labeled surrounding the indicated tubules. (C) Levels of intracellular ROS in HUVEC over a
24-h period during treatment with three diﬀerent doses of LPS (1 µg/ml, 10 µg/ml, and 20 µg/ml). Images in panel C demonstrate an increase of intracellular ROS at 24 h (as indicated by
the increase in green ﬂuorescence of CellROX; nuclei are labeled blue with Hoescht; cells are outlined in yellow in images). The line graph displays subsequent ROS quantiﬁcation. (D)
Levels of mitochondrial generated ROS in HUVEC over a 24-h period during treatment with three diﬀerent doses of LPS (1 µg/ml, 10 µg/ml, and 20 µg/ml). Images in panel D
demonstrate an increase of mitochondrial ROS at 24 h (as indicated by the increase in red ﬂuorescence of MitoSOX; nuclei are labeled blue with Hoescht; cells are outlined in yellow in
images). Subsequent quantiﬁcation is given in the line graph. (E) Levels of intracellular ROS in HK-2 cells over a 24-h period during treatment with three diﬀerent doses of LPS (1 µg/ml,
10 µg/ml, and 20 µg/ml). Images in panel E demonstrate an increase of intracellular ROS at 24 h (as indicated by the increase in green ﬂuorescence of CellROX; nuclei are labeled blue
with Hoescht; cells are outlined in yellow in images). The line graph displays subsequent ROS quantiﬁcation. (F) Levels of mitochondrial generated ROS in HK-2 cells over a 24-h period
during treatment with three diﬀerent doses of LPS (1 µg/ml, 10 µg/ml, and 20 µg/ml). Images in panel F demonstrate an increase of mitochondrial ROS at 24 h (as indicated by the
increase in red ﬂuorescence of MitoSOX; nuclei are labeled blue with Hoescht; cells are outlined in yellow in images). Subsequent quantiﬁcation is given in the line graph. Magniﬁcation
= 600x. Line bar represents 25 µm. *p ≤ 0.05 vs. control; #p≤ 0.05 vs. 24-h (1 µg/ml LPS). n = 5–9 diﬀerent cell cultures per experimental group for graphs C-F (see Supplemental
Methods online for details concerning the amount of cells analyzed in each cell culture sample). Slight corrections in brightness and contrast were made to images in Fig. 1 only for clarity.
(For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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circulation, as indicated by decreased thiol content. However, the in-
crease was statistically insigniﬁcant (Fig. 2a-c). Conversely, HMGB1
demonstrated signiﬁcant oxidation in the cytoplasmic compartment
and remained oxidized in the circulation during high LPS dose treat-
ment (Fig. 2a-c). To conﬁrm oxidation of HMGB1 in the cytoplasm of
kidney cells, we also subjected these samples to mass spectrometry
analysis. Liquid chromatography in tandem with mass spectrometry
(LC-MS/MS) conﬁrmed oxidation of HMGB1 in the cytoplasm during
LPS-induced stress. LC-MS/MS identiﬁed the oxidation of cysteine re-
sidues at positions 23 and 45 (C34 and C45) and subsequent formation
of a disulﬁde bond between these two residues during LPS treatment,
with enhanced disulﬁde bond formation as LPS-induced stress was in-
creased (Fig. 2d-f). The diﬀerence in HMGB1 thiol content during low
versus high LPS-induced stress presumably indicates a heterozygous
mixture of HMGB1 whose cysteines are still in reduced thiol form along
with cysteines that have formed a disulﬁde bond. This was similarly
observed in experiments conducted by Venereau at. al., in which su-
pernatants of THP-1 monocytes treated with LPS contained both all-
thiol and disulﬁde bonded HMGB1 [35].
Our results indicate HMGB1 becomes oxidized in the cytoplasm of
kidney cells before its release into the circulation. This ﬁnding suggests
increased intracellular generated ROS from sources such as NADPH
oxidase and dysfunctional mitochondria oxidize HMGB1 in the cyto-
plasm during its nuclear-to-cytoplasmic translocation prior to release
into the plasma. Furthermore, similar to the study by Venereau et al.
utilizing monocytes, HMGB1 in the nucleus of kidney cells remains in
reduced thiol form.
3.3. HMGB1 reduction by thioredoxin and glutathione
The thioredoxin and glutathione reduction pathways are two par-
allel, interdependent enzymatic systems present in all eukaryotic cells
[29]. While both pathways are composed of multiple enzymes, in-
cluding critical reductases, the thioredoxin and glutathione enzymes
themselves are key enzymes in their respective systems [38]. Both
systems play critical roles in the maintenance of intra-/extracellular
redox balance [30] by maintaining proteins in their reduced state
[29,39,40]. Thioredoxin and glutathione have both been shown to in-
teract and reduce isolated puriﬁed HMGB1 [32,33]. Therefore, we
questioned if these systems maintain reduction of HMGB1 during
sepsis. We ﬁrst examined total thioredoxin and glutathione activity in
the cellular compartments of kidney cells and in the circulation 24 h
after low and high LPS dose administration. Despite a negligible change
in circulating thioredoxin levels 24 h after LPS administration, the
change in intracellular and extracellular levels of thioredoxin and glu-
tathione were dependent on the severity of endotoxin stress. Speciﬁ-
cally, our results demonstrated thioredoxin activity was initially in-
creased in the nucleus and cytoplasm during mild sepsis, but as sepsis
became more severe, thioredoxin activity decreased in these compart-
ments (Fig. 3a). In contrast, glutathione activity increased signiﬁcantly
in both the nucleus and circulation as LPS-induced sepsis worsened
(Fig. 3a). Interestingly, cytoplasmic glutathione levels drastically de-
clined as sepsis worsened, suggesting the simultaneous increase of cir-
culating glutathione was a result of its enhanced release from the cy-
toplasm into the circulation.
We next examined the ability of these antioxidant systems to
maintain reduced HMGB1 within kidney cells during LPS-induced
stress. These experiments were conducted on HUVEC and HK-2 cell
cultures. A relatively low dose of LPS was implemented in these ex-
periments (10 µg/ml) as to not overwhelm the antioxidant capacity of
the thioredoxin and glutathione systems. In endothelial cells, while
inhibition of glutathione and thioredoxin had no eﬀect on HMGB1
redox in the nucleus, conversely, inhibition of either antioxidant en-
hanced HMGB1 oxidation in the cytoplasm (Fig. 3b-c). In tubular epi-
thelial cells, the thioredoxin inhibitor auranoﬁn increased HMGB1
oxidation in the nucleus and cytoplasm, while the glutathione inhibitor
L-BSO only had an inﬂuence on HMGB1 redox in the nucleus (Fig. 3d-
e). These ﬁndings indicate glutathione and thioredoxin maintain
HMGB1 in its reduced form in kidney cells during sepsis, with cell-type
and cellular-compartment dependent diﬀerences in their speciﬁc eﬀects
on HMGB1 redox.
3.4. HMGB1 redox state impacts stimulation of cyto-/chemokine release
and ATP generation
Once in the circulation, HMGB1 can stimulate the release of pro-
inﬂammatory cyto-/chemokines from various cells and tissues
[20,35,41–47]. However, the impact that the change in HMGB1 redox
has on the protein's ability to promote cyto-/chemokine release during
sepsis remains unclear. Therefore, we examined the speciﬁc cyto-/
chemokines that are systemically released in response to HMGB1 that is
oxidized to diﬀerent extents due to diﬀerences in sepsis severity. For
these experiments, HMGB1 was captured from the circulation of mice
24 h after treatment with either low (10 µg/kg) or high (1 mg/kg) LPS
dose. HMGB1 was also captured from the circulation of control animals.
The puriﬁed HMGB1 was then intravenously administered to healthy
mice. After 6 h, cyto-/chemokine levels in the circulation was measured
by Luminex Multiplex. As HMGB1 became more oxidized, the protein's
ability to stimulate systemic release of pro-inﬂammatory cyto-/che-
mokines was enhanced, particularly regarding release of IL-1β, IL-17,
TNFα, MIP-1α, MIP-1β, MIP-2, G-CSF and GM-CSF (Fig. 4a).
Sepsis is characterized by an increase in total cellular metabolism in
order to provide the energy needed to sustain immune system activa-
tion [22]. However, the molecules that stimulate the hypermetabolic
state are uncertain. When isolated mitochondria (puriﬁed from whole
kidney homogenates) were treated with low and high oxidized HMGB1,
mitochondrial ATP generation increased (Fig. 4b). As HMGB1 oxidi-
zation increased, its stimulatory eﬀect on ATP generation was en-
hanced. This suggests HMGB1 and its oxidative state plays a role in
stimulating a hypermetabolic state during sepsis.
4. Conclusions
During sepsis, oxidative stress increases in the kidney, which leads
to oxidation of HMGB1 during its release from kidney cells. Oxidation
of HMGB1 enhances its pro-inﬂammatory signaling. However, glu-
tathione and thioredoxin work to maintain HMGB1 in a reduce state in
kidney cells.
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Fig. 2. Sepsis-induced oxidative stress leads to oxidation of HMGB1. HMGB1 thiol content in the (A) nuclear and (B) cytoplasmic compartments of kidney cells and in the (C) plasma
24 h after treatment with either low (10 µg/kg) or high (1 mg/kg) LPS dose. *p≤ 0.05 vs. control; n = 5. (D-F) LC-MS/MS analysis was conducted on cytoplasmic fractions to conﬁrm
HMGB1 oxidation in the cytoplasm. (D) LC-MS/MS spectra trace of kidney cytoplasmic samples show two HMGB1 peptides with a retention time of 29.01 mins that are connected by a
disulﬁde bond between C23 and C45 (peptide sequences are indicated in the ﬁgure). The disulﬁde bonded peptides appear as a peak at 477 m/z (identiﬁed as disulﬁde bond between C23
and C45 by MassMatrix software analysis). The absence of the thiol marker iodoacetamide and sulfonate marker dimedone further indicates these two cysteines are disulﬁde bonded. (E)
Sample comparison of the elution traces (and subsequent area assignments) of disulﬁde bonded peptides with a peak of 477 m/z and a retention time of 29.01 mins. Samples compared
included HMGB1 isolated from cytoplasmic fractions of mice whole kidneys 24 h after mice were treated with low and high LPS dose. (F) Quantiﬁcation of the elution trace area
assignments representative of the amount of HMGB1 C23-C45 disulﬁde bonded in each sample. Statistical signiﬁcance is not given in panel F because multiple (n = 5) individual samples
were pooled together and analyzed collectively for each of the three sample conditions.
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Fig. 3. Glutathione and thioredoxin maintain HMGB1 in reduced form during sepsis. (A) Glutathione and thioredoxin activity in the nuclear and cytoplasmic compartments of
fractionated whole kidneys and in the plasma 24 h after mice were treated with low (10 µg/kg) or high (1 mg/kg) LPS dose. Values in the graphs are represented by percent change relative to
control. n = 4–5 (except thioredoxin plasma and cytoplasm treated with 10 µg/kg of LPS, which had an n = 3). Thiol content of HMGB1 localized in the (B) nucleus and (C) cytoplasm of
HUVEC 24 h after treatment with LPS (10 µg/ml) and speciﬁc inhibitors of glutathione (L-BSO) or thioredoxin (Auranoﬁn). *p≤ 0.05 vs. control. n = 4–5. Thiol content of HMGB1 localized
in the (D) nucleus and (E) cytoplasm of HK-2 cells 24 h after treatment with LPS (10 µg/ml) and L-BSO or Auranoﬁn. *p ≤ 0.05 vs. control; †p≤0.10 vs. control. n = 4–5.
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